课题基金 / 基金详情

项目摘要

项目成果

JOEL N BLANKSON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: There has been a lot of optimism about potentially eradicating HIV-1 using strategies such as reactivation of latently infected cells by small molecules. A recent study has suggested that this approach may in fact be possible; a single dose of the molecule vorinostat was shown to induce HIV expression in CD4+ T cells in vivo. While this strategy may end up being effective, it may be very challenging to reactivate every last latently infected CD4+ T cell. A complementary strategy may be to physically eliminate latently infected cells using antibodies conjugated to toxins. This may be analogous to surgically "debulking" a tumor prior to initiating chemotherapy. However, targeting latently infected CD4+ T cells has been a challenging task because the phenotype of these cells remains largely unknown. In this new proposal, we plan to use antibodies to more than 200 different T cell markers in order to determine the phenotype of latently infected CD4+ T cells. Such an approach has been successfully used to determine the phenotype of activated T cells in a recent study. This will be analogous to screening for small molecules that activate latently infected CD4+ T cells, but in this case, a library of monoclonal antibodies (Mabs) rather than compounds will be used and the readout will be binding of Mabs to infected resting CD4+ T cells or recently reactivated latently infected CD4+ T cells rather than reactivation itself. We plan to validate our results by sorting resting CD4+ T cells from HIV-1 infected patients on suppressive HAART regimens. We specifically will sort for markers that are identified in our screen to determine whether there is an overrepresentation of HIV-1 DNA and latent replication-competent virus in these cells. This work will have major implications for strategies for HIV-1 eradication since it will potentially lead to the clearance of latently infectd cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Eradication of clonally expanded CD4+ T cells
  • 批准号:
    10621808
  • 项目类别:
  • 资助金额:
    $20.47万
  • 财政年份:
    2022
  • 负责人:
    JOEL N BLANKSON
  • 依托单位:
Eradication of clonally expanded CD4+ T cells
  • 批准号:
    10548015
  • 项目类别:
  • 资助金额:
    $24.56万
  • 财政年份:
    2022
  • 负责人:
    JOEL N BLANKSON
  • 依托单位:
mRNA vaccine responses in PLWH
  • 批准号:
    10687989
  • 项目类别:
  • 资助金额:
    $20.47万
  • 财政年份:
    2022
  • 负责人:
    JOEL N BLANKSON
  • 依托单位:
mRNA vaccine responses in PLWH
  • 批准号:
    10402541
  • 项目类别:
  • 资助金额:
    $24.56万
  • 财政年份:
    2022
  • 负责人:
    JOEL N BLANKSON
  • 依托单位:
海外基金